Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Vivus
 More »

  • Auxilium Licenses Stendra from Vivus for Up to $300M
    Canada, in a licensing deal that could generate up to $300 million for Vivus. Auxilium agreed to pay Vivus $30 million up front, plus a $15 million milestone payment if the FDA ...
    10-11-2013
  • Double Manufacturing Deals for Sanofi
    Two Sanofi companies have entered biomanufacturing deals with Vivus and Gallus Biopharmaceuticals. Sanofi subsidiary Sanofi Chimie has made an agreement with Vivus to manufacture ...
    8-1-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    (phentermine and topiramate extended-release) 2012 sales: $2 million Marketer(s): Vivus Indication(s): Chronic weight management in adults with an initial body mass index ...
    4-4-2013
  • Biggest Biotech Trends of 2012
    The world didn't come to an end in 2012, but the biopharma world ended the year holding its breath, as President Obama and Congress struggled to craft a budget deal and avoid the ...
    1-15-2013
  • Getting FDA to Yes
    As PDUFA, patent cliff drive 2012 approvals, can industry keep cranking out new molecules? Years of industry complaints appeared to pay off when the clock struck midnight on New ...
    1-8-2013
  • 7 Biotech Trends for the Coming Year
    What does 2013 hold for the industry? America didn't fall off the fiscal cliff when the clock struck midnight on New Year's Eve, yet 2013 still presents numerous additional ...
    1-3-2013
  • Biggest Biotech Trends of 2012
    GEN takes a look back at some key biopharma developments of the past 12 months. The world didn't come to an end in 2012, but the biopharma world ended the year holding its breath, ...
    12-26-2012
  • FSD Drugs Advance as Women Push for Equal Access
    Drug development in this arena has proven difficult, but some successes have been reported recently. While men have had Viagra (sildenafil), Cialis (tadalafil), and Levitra ...
    11-20-2012
  • Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs...
    For many of us, the New Year brings resolutions; a hopeful promise to do things better next time. For biotechs, it brings new data; data that can sink or save a product, a ...
    9-5-2012
  • Obesity Drug Developers Post Steady Gains
    The FDA resembled a longtime dieter splurging on a hearty meal over the summer when, within 20 days, it approved the first two new obesity treatments in more than a decade. Vivus ...
    9-5-2012
  • FDA Clears Vivus' Anti-Obesity Drug Qsymia
    Vivus is also charged with carrying out postmarketing studies to assess the long-term effects of Qsymia therapy on major adverse cardiovascular events in overweight and obese ...
    7-18-2012
  • People in the News
    medical director and added Ronald J. Wapner, M.D. , to its scientific advisory board...Vivus appointed Ernest Mario, Ph.D. , to serve on its board of directors...Sanguine ...
    6-1-2012
  • This Time Last Year: Diagnostic Deals, mAb Therapeutics, and...
    ... This February brought some good news for another obesity drug. Vivus reported that FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended its Qnexa be granted ...
    5-30-2012
  • Regulatory Environment Warms Up to Obesity Drugs
    One of the questions raised during the February Qnexa panel was whether Vivus should ... Vivus says it designed and developed the drug to decrease appetite and increase satiety. ...
    4-15-2012
  • 2-to-1 Majority of Respondents to a GEN Poll See Smooth Sailing...
    Qnexa's developer Vivus received welcome news on February 22 when an FDA advisory ... Since then, Vivus conducted a one-year clinical trial with new data, while only 12 ...
    4-4-2012

  • Journal Articles

  • Development of a Test System for Homeopathic Preparations Using...
    Tim Jäger, Claudia Scherr, Meinhard Simon, Peter Heusser, Stephan Baumgartner
    Journal of Alternative and Complementary Medicine, The
    Conchae, Acidum picrinicum, Argentum nitricum, Crotalus horridus, Hepar sulfuris, and Mercurius vivus naturalis. Design: Duckweed was stressed with arsenic(V) for 48 hours. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll